Merck & Company (NYSE:MRK) Receives a Lower Rating From Morgan Stanley. Will This be Detrimental to the Share Price?

January 19, 2018 - By Migdalia James

  Merck & Company (NYSE:MRK) Receives a Lower Rating From Morgan Stanley. Will This be Detrimental to the Share Price?

Investors sentiment decreased to 1.06 in Q3 2017. Its down 0.01, from 1.07 in 2017Q2. It dropped, as 46 investors sold Merck & Co., Inc. shares while 619 reduced holdings. 106 funds opened positions while 598 raised stakes. 1.96 billion shares or 0.47% more from 1.95 billion shares in 2017Q2 were reported.

6.47 million are owned by Arrowstreet Ltd Partnership. Carl Domino owns 1.43% invested in Merck & Co., Inc. (NYSE:MRK) for 18,311 shares. Kazazian Asset Mngmt Ltd Limited Liability Company holds 0.91% or 11,662 shares. Capital Lc has 64,956 shares for 0.29% of their portfolio. Moreover, Hourglass has 0.11% invested in Merck & Co., Inc. (NYSE:MRK). Moreover, Amf Pensionsforsakring has 1.97% invested in Merck & Co., Inc. (NYSE:MRK). Shine Advisory invested 0.21% in Merck & Co., Inc. (NYSE:MRK). Main Street Rech Limited Co has 12,784 shares. Azimuth Capital Management Limited Liability Corp holds 1.17% or 244,377 shares. Jennison Lc holds 0.13% of its portfolio in Merck & Co., Inc. (NYSE:MRK) for 1.92 million shares. Sg Americas Lc accumulated 206,123 shares. Marsico Cap Mngmt Ltd Liability Corporation reported 647,883 shares stake. Bahl And Gaynor accumulated 2.26M shares. Barclays Plc reported 3.55M shares stake. Eagle Ridge Inv Mgmt owns 6,056 shares.

Merck & Company (NYSE:MRK) Receives a Downgrade

In a note revealed to clients and investors moments ago, Morgan Stanley decreased their rating for shares of Merck & Company (NYSE:MRK) to a Hold. Analysts currently have set a $56.0 target price per share on the stock. Morgan Stanley’s target price per share indicates a possible downside of -7.99 % from the last close price of the stock.

Investors sentiment decreased to 1.06 in Q3 2017. Its down 0.01, from 1.07 in 2017Q2. It dropped, as 46 investors sold Merck & Co., Inc. shares while 619 reduced holdings. 106 funds opened positions while 598 raised stakes. 1.96 billion shares or 0.47% more from 1.95 billion shares in 2017Q2 were reported.

6.47 million are owned by Arrowstreet Ltd Partnership. Carl Domino owns 1.43% invested in Merck & Co., Inc. (NYSE:MRK) for 18,311 shares. Kazazian Asset Mngmt Ltd Limited Liability Company holds 0.91% or 11,662 shares. Capital Lc has 64,956 shares for 0.29% of their portfolio. Moreover, Hourglass has 0.11% invested in Merck & Co., Inc. (NYSE:MRK). Moreover, Amf Pensionsforsakring has 1.97% invested in Merck & Co., Inc. (NYSE:MRK). Shine Advisory invested 0.21% in Merck & Co., Inc. (NYSE:MRK). Main Street Rech Limited Co has 12,784 shares. Azimuth Capital Management Limited Liability Corp holds 1.17% or 244,377 shares. Jennison Lc holds 0.13% of its portfolio in Merck & Co., Inc. (NYSE:MRK) for 1.92 million shares. Sg Americas Lc accumulated 206,123 shares. Marsico Cap Mngmt Ltd Liability Corporation reported 647,883 shares stake. Bahl And Gaynor accumulated 2.26M shares. Barclays Plc reported 3.55M shares stake. Eagle Ridge Inv Mgmt owns 6,056 shares.

Merck & Co., Inc. (NYSE:MRK) Ratings Coverage

Among 23 analysts covering Merck & Co. Inc. (NYSE:MRK), 16 have Buy rating, 0 Sell and 7 Hold. Therefore 70% are positive. Merck & Co. Inc. has $7400 highest and $50 lowest target. $66.44’s average target is 9.17% above currents $60.86 stock price. Merck & Co. Inc. had 73 analyst reports since August 13, 2015 according to SRatingsIntel. The company was maintained on Tuesday, November 28 by Bank of America. The firm earned “Buy” rating on Wednesday, November 15 by Bernstein. The rating was downgraded by Morgan Stanley to “Equal-Weight” on Monday, October 30. The stock of Merck & Co., Inc. (NYSE:MRK) earned “Buy” rating by SunTrust on Friday, July 28. The company was maintained on Tuesday, November 17 by Argus Research. The firm has “Neutral” rating by Credit Suisse given on Monday, May 9. The firm earned “Overweight” rating on Thursday, January 12 by Morgan Stanley. The stock of Merck & Co., Inc. (NYSE:MRK) earned “Overweight” rating by Barclays Capital on Friday, September 9. The firm has “Hold” rating by Jefferies given on Friday, April 15. The rating was maintained by Jefferies with “Hold” on Tuesday, June 14.

The stock decreased 0.44% or $0.27 during the last trading session, reaching $60.86. About 5.26M shares traded. Merck & Co., Inc. (NYSE:MRK) has risen 16.86% since January 19, 2017 and is uptrending. It has outperformed by 0.16% the S&P500.

Analysts await Merck & Co., Inc. (NYSE:MRK) to report earnings on February, 1. They expect $0.94 EPS, up 5.62 % or $0.05 from last year’s $0.89 per share. MRK’s profit will be $2.56B for 16.19 P/E if the $0.94 EPS becomes a reality. After $1.11 actual EPS reported by Merck & Co., Inc. for the previous quarter, Wall Street now forecasts -15.32 % negative EPS growth.

Merck & Co., Inc. provides healthcare solutions worldwide. The company has market cap of $165.81 billion. It operates in four divisions: Pharmaceutical, Animal Health, Healthcare Services, and Alliances divisions. It has a 58.92 P/E ratio. The firm offers therapeutic agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal and intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

More notable recent Merck & Co., Inc. (NYSE:MRK) news were published by: Twst.com which released: “Merck & Co. Inc.: LYNPARZA® (olaparib) Receives Approval in Japan for the …” on January 19, 2018, also Investorplace.com with their article: “Merck & Co., Inc. Stock Could Still Soar Another 10% From Here” published on January 18, 2018, Investorplace.com published: “Merck & Co., Inc.’s Rally Could Burn Investors” on January 19, 2018. More interesting news about Merck & Co., Inc. (NYSE:MRK) were released by: Seekingalpha.com and their article: “Merck: Elucidating The Ramifications Of The Recent Keynote Findings” published on January 17, 2018 as well as Investorplace.com‘s news article titled: “After Irrational Fire Sale, It’s Time to Buy the Dip in Merck & Co., Inc. Stock” with publication date: January 09, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.